Leiascully
LightNews LightNews
banner
leiascully.bsky.social
Leiascully
@leiascully.bsky.social
280 followers 200 following 120 posts
The usual nonsense. She/they.
Posts Replies Media Videos
leiascully.bsky.social
Hell yeah (oh nooooo)
December 2, 2025 at 10:15 PM
Reposted by Leiascully
sydney-bauer.com
Yeah, like at this point this was a student very clearly recruited to bait this kind of situation. And because academic discipline is never a neutral situation it’ll work: bsky.app/profile/cait...
caitlinmoriah.bsky.social dr. caitlin m. green @caitlinmoriah.bsky.social · 2d
a lot of people debating the merits of that dogshit essay meanwhile the girl’s mom is retweeting demands to ban all trans people from teaching at any level. it’s forest for the trees shit
December 1, 2025 at 1:03 PM
Reposted by Leiascully
sailorrooscout.bsky.social
Their efficacy was confirmed against LIVE viruses including Ebola, Marburg, Nipah, Hendra, SARS-CoV, SARS-CoV-2 (COVID-19), AND Middle East Respiratory Syndrome (MERS).

The study has been published in Science Advances. YES, it is PEER-REVIEWED.
• www.science.org/doi/10.1126/...

🧪🧵⬇️
ABSTRACT Viral pandemics continue to threaten global health and economic stability. Despite medical advances, the absence of broad-spectrum antivirals (BSAs) prevents rapid responses to emerging viral threats. This is largely due to the lack of universal drug targets across diverse viral families and high variability among viral proteins. In this study, we evaluated 57 synthetic carbohydrate receptors (SCRs) for antiviral activity in cellulo using pseudotyped virus particles (PVPs) from six high-risk viruses across three families: Paramyxoviridae, Filoviridae, and Coronaviridae. Four SCRs inhibited all tested PVPs, and their efficacy was confirmed against live viruses including SARS-CoV-2, MERS-COV, EBOV, MARV, NiV, and HeV. Notably, SCR005 and SCR007, which exhibited minimal toxicity, significantly reduced SARS-CoV-2 infection in a severe animal model with a single dose. Mechanistic studies suggested that SCRs bind viral envelope N-glycans, blocking viral attachment and/or fusion. These results identify conserved viral N-glycans as promising BSA targets and establish SCRs as candidate prophylactic agents against enveloped viruses with pandemic potential.
November 28, 2025 at 5:02 PM